Drug intelligence / Profile preview

PEi

Development stage: Preclinical
Lead developer: Antabio
Modality: Small Molecules
Administration: Inhalation

Overview

PEi refers to a small molecule drug candidate being developed by ANTABIO as part of its PEi program. This inhaled drug is designed to act as an adjunct to existing antibiotic therapy, aiming to reduce the frequency and severity of Pseudomonas exacerbations. Its mechanism of action involves targeting both the virulence and persistence of biofilm-adapted infections, specifically by inhibiting the LasB elastase virulence factor of Pseudomonas aeruginosa. The drug is intended for patients at risk due to cystic fibrosis.

Targets

LasB (Pseudomonas aeruginosa elastase)

Beyond the preview

Go deeper on PEi.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PEi.

Explore the full profile